In Wednesday's filing, lawyers representing the Glumetza buyers said the $300 million “represents an excellent result.” The deal follows a May ruling from U.S. RELATED: Valeant's price-hike strategy goes far beyond two high-profile increases By 2016, Glumetza was raking in roughly $1.2 billion, according to the lawsuit. That allowed the companies to jack up the price for Glumetza by nearly 800% in 2015, jumping from $5.72 per tablet to $51 just a few months later, according to the lawsuit. However, the lawsuit alleged that Assertio and Santarus entered what’s known as a “pay-for-delay” deal with Lupin, pushing its market entry back until 2016. RELATED: Depomed joins ranks of scandal-plagued pharmas rehabbing their reputations with a name changeĮnter Lupin Pharmaceuticals, which created its own generic version of Glumetza set to launch in late 2012. Except the patents were “both weak and easy to design around,” the plaintiff lawyers argued. The Glumetza version of metformin is intended to come with fewer gastrointestinal side effects.Īssertio attempted to create a lawful patent wall around its newly approved extended-release version of the drug, given that the company couldn’t patent metformin itself, the lawsuit claimed. Bausch’s troubles date all the way back to 2005 when the FDA first approved Glumetza, a once-daily extended-release version of metformin, owned by Depomed (now known as Assertio) and Santarus, which Bausch later acquired.

Bausch pharmaceutical